Biotime-Nasdaq's best kept secret? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret?

BTIM 0.0001000

0.0%

Nov 5 1:26 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Stephen How who wrote (792)	3/31/1998 8:58:00 AM
From: Jim Roof	Read Replies (1) of 1432

I see no problem with Hextend cannibalizing Abbott's existing generic. I would expect it to frankly. The key is the bottom line. The profitability of Hextend should not be evaluated on a per liter basis but on a total sales figure. If Abbott loses 15% on each liter of Hextend as compared to hetastarch but sells 30% more then the bottom line is enhanced. There is a lot of discussion of the lack of 'statistical significance' of some of the purported advantages of Hextend over the generics and I understand the need for statistical significance to be reached. However, one must consider that the fault lies not with Hextend but with the study. From a non-statistically significant viewpoint Hextend was ahead in every consideration. Certainly such bias taken as a whole could not be the result of chance. Given a correct interpretation of the data I recall no area in which the generic hetastarch was statistically better than Hextend - significant or not. Can you? Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next